HARVARD BIOSCIENCE develops, manufactures and markets tools used in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories.
| Revenue (Most Recent Fiscal Year) | $86.55M |
| Net Income (Most Recent Fiscal Year) | $-56.70M |
| PE Ratio (Current Year Earnings Estimate) | 5.57 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.32 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.00 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 0.52 |
| Pre-Tax Margin (Trailing 12 Months) | -66.30% |
| Net Margin (Trailing 12 Months) | -65.51% |
| Return on Equity (Trailing 12 Months) | -19.54% |
| Return on Assets (Trailing 12 Months) | -3.59% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.20 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.25 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 2.61 |
| Inventory Turnover (Trailing 12 Months) | 1.68 |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.10 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.60 |
| Diluted Earnings per Share (Trailing 12 Months) | $-12.80 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Common Shares Outstanding | 4.47M |
| Free Float | 3.56M |
| Market Capitalization | $27.41M |
| Average Volume (Last 20 Days) | 0.07M |
| Beta (Past 60 Months) | 1.50 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 80.87% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |